Oncgnostics GmbH specializes in molecular biological cancer diagnostics, focusing on the development of innovative methylation tests that can replace invasive diagnostic methods. Their flagship products, GynTect and ScreenYu Gyn, are designed for cervical cancer screening and are already in use across several European countries, as well as under exclusive license in China. GynTect is notable for its ability to significantly reduce the number of unnecessary colposcopies by up to 75%, providing quick and reliable results that address gaps in the evaluation of screening anomalies. ScreenYu Gyn, an advancement of GynTect, utilizes a single methylated DNA region, allowing for automation and expanding its potential applications.

In addition to cervical cancer diagnostics, Oncgnostics is developing a methylation test for the non-invasive detection of head and neck tumors through liquid biopsies, such as saliva and oral swabs. This initiative aims to address the challenges of identifying tumor recurrences in clinical practice, where rapid and straightforward diagnostic solutions are often lacking. The company leverages a robust international network of study centers to gather extensive data on the efficacy of epigenetic tumor markers for detecting head and neck cancers, further solidifying its commitment to advancing cancer diagnostics through innovative, non-invasive methodologies.

Germany

oncgnostics develops – based on proprietary epigenetic biomarkers - highly reliable molecular in vitro diagnostic (IVD) tests for screening, follow-up care and therapeutic decisions in cancer diagnostics.

Oncgnostics

Company Details